Indaptus Therapeutics, Inc. — Form SCHEDULE 13D/A
Filed October 22, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 15/100
What the filing says
This is an amended Schedule 13D/A filing dated October 22, 2026, by Dai Junyi regarding beneficial ownership in Indaptus Therapeutics, Inc. (CIK 0001857044). The filing document itself contains no substantive disclosure of ownership percentages, share counts, transaction amounts, or specific changes to beneficial ownership—only header information and filing metadata. Critical details needed to assess the materiality of any ownership change are absent from the provided text.
Why this rating
No concrete ownership data disclosed in excerpt; amendment status suggests prior change, but specifics unavailable. Routine disclosure filing.
See more from October 22, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.